BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

This study tests whether adding BAT1308 — an immunotherapy that blocks the PD-1 checkpoint — to standard platinum-based chemotherapy (with or without bevacizumab, a drug that slows tumor blood vessel growth) can improve outcomes for women with advanced, persistent, or recurrent cervical cancer whose tumors express the PD-L1 protein. **You may be eligible if...** - You are a woman aged 18–70 with confirmed cervical cancer (squamous cell, adenocarcinoma, adenosquamous, or clear-cell type) - Your cancer is persistent, recurrent, or has spread to distant organs (stage IVB) and cannot be cured with surgery or radiation - You have not received prior systemic treatment for advanced or recurrent cervical cancer - Your tumor tests positive for PD-L1 (CPS ≥1) - You are in good overall health (ECOG 0 or 1) with a life expectancy of at least 12 weeks **You may NOT be eligible if...** - You have received prior chemotherapy or immunotherapy for recurrent or metastatic cervical cancer - You are pregnant or have significant organ dysfunction - You have uncontrolled infection, active autoimmune disease, or significant cardiovascular disease Talk to your doctor to see if this trial is right for you.